KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
RXDX-105 Sensitive: C3 – Early Trials
|
RXDX-105 Sensitive: C3 – Early Trials
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
vandetanib Sensitive: C3 – Early Trials
|
vandetanib Sensitive: C3 – Early Trials
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
nintedanib Sensitive: C3 – Early Trials
|
nintedanib Sensitive: C3 – Early Trials
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
KIF5B-RET fusion
|
Lung Cancer
|
KIF5B-RET fusion
|
Lung Cancer
|
alectinib Resistant: C3 – Early Trials
|
alectinib Resistant: C3 – Early Trials
|
KIF5B-RET fusion
|
LUAD
|
KIF5B-RET fusion
|
LUAD
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
pembrolizumab Resistant: C4 – Case Studies
|
pembrolizumab Resistant: C4 – Case Studies
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
selpercatinib Resistant: C4 – Case Studies
|
selpercatinib Resistant: C4 – Case Studies
|
KIF5B-RET fusion
|
LUAD
|
KIF5B-RET fusion
|
LUAD
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
cabozantinib tablet Resistant: C4 – Case Studies
|
cabozantinib tablet Resistant: C4 – Case Studies
|
KIF5B-RET fusion
|
LUAD
|
KIF5B-RET fusion
|
LUAD
|
cabozantinib tablet Sensitive: D – Preclinical
|
cabozantinib tablet Sensitive: D – Preclinical
|
KIF5B-RET fusion
|
LUAD
|
KIF5B-RET fusion
|
LUAD
|
vandetanib Sensitive: D – Preclinical
|
vandetanib Sensitive: D – Preclinical
|
KIF5B-RET fusion
|
NSCLC
|
KIF5B-RET fusion
|
NSCLC
|
pralsetinib Sensitive: D – Preclinical
|
pralsetinib Sensitive: D – Preclinical
|